COMPANION-002
CTX-009-002
Biliary Tract Cancer (BTC)
A Phase 2/3 study in adults with unresectable, advanced, metastatic or recurrent biliary tract cancer who have received one prior systemic chemotherapy regimen. This randomized study assesses the efficacy and safety of CTX-009 in combination with paclitaxel versus paclitaxel alone as a second-line therapy. The primary outcome is Overall Response Rate (ORR). Study enrollment is now closed.
Watch our presentation
COMPANION-003
CTX-009-003
Colorectal Cancer
A Phase 2 study in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. This study assesses the efficacy and safety of CTX-009. The primary outcome is ORR (Overall Response Rate). Study enrollment is now closed.
CTX-471 + KEYTRUDA®
(pembrolizumab)
Solid Tumors
A Phase 1b arm for patients who have metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer who have progressed after treatment with a checkpoint inhibitor. Patients enrolled in the study are treated with a combination of CTX-471 + KEYTRUDA® (pembrolizumab) with the goal of restoring response. Study enrollment is now closed.
CTX-8371
A Phase 1, multiple–ascending dose study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetic profile of CTX-8371 monotherapy in patients with metastatic Malignant Melanoma, Head and Neck squamous cell carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, and Classical Hodgkin Lymphoma. Preliminary anti-tumor activity of CTX-8371 will also be assessed.
COMPANION-002 Trial Locations
Compass Therapeutics is committing to conducting rigorous and ethical research. Our clinical studies, and the associated protocols, are approved by the appropriate ethics committee or institutional review board at each participating center. Our clinical study protocol and procedures are established to ensure compliance with any applicable governmental regulations, ethical guidelines, and institutional requirements, including the Declaration of Helsinki, the US FDA, and applicable institutional bylaws.